Deciphera Pharmaceuticals, Inc. to Present at the 41st Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary

Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) has announced that CEO Steve Hoerter will present at the 41st Annual J.P. Morgan Healthcare Conference on January 9, 2023, at 9:45 AM PT. A live webcast of the presentation will be accessible via the company’s website, with a replay available for 30 days afterward. Deciphera focuses on developing innovative cancer treatments, utilizing its proprietary switch-control kinase inhibitor platform. The company's QINLOCK® is already approved in several markets, including the United States and Europe.

WALTHAM, Mass.--(BUSINESS WIRE)-- Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) today announced that Steve Hoerter, President and Chief Executive Officer, will present at the 41st Annual J.P. Morgan Healthcare Conference on Monday, January 9, 2023, at 9:45 AM PT.

A live webcast of the event will be available on the “Events and Presentations” page in the “Investors” section of the Company’s website at https://investors.deciphera.com/events-presentations. A replay will be archived on the Company’s website for 30 days following the presentation.

About Deciphera Pharmaceuticals

Deciphera is a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer. We are leveraging our proprietary switch-control kinase inhibitor platform and deep expertise in kinase biology to develop a broad portfolio of innovative medicines. In addition to advancing multiple product candidates from our platform in clinical studies, QINLOCK^® is Deciphera’s switch control inhibitor for the treatment of fourth-line GIST. QINLOCK is approved in Australia, Canada, China, the European Union, Hong Kong, Switzerland, Taiwan, the United Kingdom, and the United States. For more information, visit www.deciphera.com and follow us on LinkedIn and Twitter (@Deciphera).

View source version on businesswire.com: https://www.businesswire.com/news/home/20230103005113/en/

Investor Relations:

Maghan Meyers

Argot Partners

Deciphera@argotpartners.com

212-600-1902

Media:

David Rosen

Argot Partners

david.rosen@argotpartners.com

212-600-1902

Source: Deciphera Pharmaceuticals, Inc.

FAQ

When will Deciphera Pharmaceuticals present at the J.P. Morgan Healthcare Conference?

Deciphera Pharmaceuticals will present on January 9, 2023, at 9:45 AM PT.

How can I watch the Deciphera Pharmaceuticals presentation?

The presentation will be available via a live webcast on the company’s website in the 'Events and Presentations' section.

What is the focus of Deciphera Pharmaceuticals?

Deciphera Pharmaceuticals focuses on discovering and developing new medicines for cancer treatment.

Is QINLOCK approved in the United States?

Yes, QINLOCK® is approved for use in the United States.

Where else is QINLOCK approved?

QINLOCK is also approved in several regions, including the European Union, Canada, and Australia.